Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 18.68 as of 2026-10-06T18:22:52.913Z.
Consensus retrieved: 2026-10-06T16:18:48.737Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T18:22:52.913Z.
Quote observation: 2026-10-06T18:20:08.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 80c0087f10925e9d716cd83ff7def583a0b1dbf49a593a6cb7c4ace42310e423
Forward PE Ratio (18.68) = Dated Quote Price ($18.39) / Consensus Forward EPS ($0.98)
FORWARD PE RATIO
18.68
SECTOR MEDIAN · HEALTHCARE
19.90
median of 191 covered companies
CURRENT VS SECTOR MEDIAN
-6.13%
vs the sector median at left
Sotera Health Company
Market Cap
$5.24B
Forward PE Ratio
18.68
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Sotera Health Company (SHC) | $5.24B | 18.68 |
| CRISPR Therapeutics AG (CRSP)vs › | $5.27B | N/A |
| Doximity, Inc. (DOCS)vs › | $5.28B | 20.95 |
| Cogent Biosciences, Inc. (COGT)vs › | $5.17B | N/A |
| Travere Therapeutics, Inc. (TVTX)vs › | $5.16B | N/A |
| PTC Therapeutics, Inc. (PTCT)vs › | $5.33B | 50.30 |
| Scholar Rock Holding Corporation (SRRK)vs › | $5.08B | N/A |
| Merit Medical Systems, Inc. (MMSI)vs › | $5.06B | 19.70 |
| Waystar Holding Corp. (WAY)vs › | $5.04B | 15.73 |
| Erasca, Inc. (ERAS)vs › | $5.00B | N/A |
Trailing P/E
32.1
reported TTM EPS
Forward P/E
18.7
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $0.98 implies +71.9% EPS growth vs the reported trailing $0.57.
At the dated quote price of $18.39, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $0.98 | $0.98 – $0.99 | 5 | 18.7x |
| 2027-12-31 | $1.07 | $1.06 – $1.09 | 5 | 17.1x |
| 2028-12-31 | $1.19 | $1.05 – $1.33 | 2 | 15.5x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
